Continuous increase of immunoglobulin therapy in Iceland

Clinical Immunology Communications Pub Date : 2022-12-01 DOI:10.1016/j.clicom.2022.06.001

Valgeir Steinn Runólfsson , Björn Rúnar Lúdvíksson , Rannveig Einarsdóttir , Þórunn Óskarsdóttir , Valtýr Thors , Ásgeir Haraldsson

{"title":"Continuous increase of immunoglobulin therapy in Iceland","authors":"Valgeir Steinn Runólfsson , Björn Rúnar Lúdvíksson , Rannveig Einarsdóttir , Þórunn Óskarsdóttir , Valtýr Thors , Ásgeir Haraldsson","doi":"10.1016/j.clicom.2022.06.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The use of immunoglobulin treatment has been increasing for various indications. The objective of this study was to evaluate clinical use of immunoglobulin therapy in Iceland, estimate off-label usage and describe possible changes in this treatment option.</p></div><div><h3>Methods</h3><p>All prescriptions for intravenous or subcutaneous immunoglobulin treatment require authorisation from Landspitali University Hospital. Patient information is registered and was retrieved for the period 2010 to 2019.</p></div><div><h3>Results</h3><p>A total of 921 patients received immunoglobulin treatment in the study period, intravenous therapy was given in 895 (97.2%) of the cases. Registered indications were 667, off-label indications were 245 and uncertain were nine. The total annual number of patients receiving immunoglobulin treatment increased from 87 in 2010 to 392 in 2019. The increase in immunoglobulin usage was both for registered and off-label indications, 61 to 309 and 26 to 83, respectively.</p></div><div><h3>Conclusion</h3><p>Continually increasing demand and global shortage dictates careful consideration of indications before initiating or continuing treatment with immunoglobulins.</p></div><div><h3>Key Message</h3><p>With global shortage of immunoglobulins, careful consideration and patient selection is important.</p></div><div><h3>Capsule Summary</h3><p>Increasing immunoglobulin usage improves treatment for many patients. However, immunoglobulins are a limited resource and prudent use is imperative.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000166/pdfft?md5=d2e9a1c98031d58c62b43968b92b97b0&pid=1-s2.0-S2772613422000166-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772613422000166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The use of immunoglobulin treatment has been increasing for various indications. The objective of this study was to evaluate clinical use of immunoglobulin therapy in Iceland, estimate off-label usage and describe possible changes in this treatment option.

Methods

All prescriptions for intravenous or subcutaneous immunoglobulin treatment require authorisation from Landspitali University Hospital. Patient information is registered and was retrieved for the period 2010 to 2019.

Results

A total of 921 patients received immunoglobulin treatment in the study period, intravenous therapy was given in 895 (97.2%) of the cases. Registered indications were 667, off-label indications were 245 and uncertain were nine. The total annual number of patients receiving immunoglobulin treatment increased from 87 in 2010 to 392 in 2019. The increase in immunoglobulin usage was both for registered and off-label indications, 61 to 309 and 26 to 83, respectively.

Conclusion

Continually increasing demand and global shortage dictates careful consideration of indications before initiating or continuing treatment with immunoglobulins.

Key Message

With global shortage of immunoglobulins, careful consideration and patient selection is important.

Capsule Summary

Increasing immunoglobulin usage improves treatment for many patients. However, immunoglobulins are a limited resource and prudent use is imperative.

查看原文本刊更多论文

冰岛免疫球蛋白治疗持续增加

背景免疫球蛋白治疗在各种适应症中的应用越来越多。本研究的目的是评估冰岛免疫球蛋白治疗的临床使用，估计标签外使用情况，并描述这种治疗方案可能发生的变化。方法所有静脉注射或皮下注射免疫球蛋白的处方均需获得兰德斯皮塔利大学医院的批准。注册并检索了2010年至2019年期间的患者信息。结果研究期间共921例患者接受免疫球蛋白治疗，其中895例(97.2%)患者接受静脉注射治疗。注册适应症667例，说明书外适应症245例，不确定适应症9例。每年接受免疫球蛋白治疗的患者总数从2010年的87人增加到2019年的392人。免疫球蛋白的使用在注册适应症和说明书外适应症中均有所增加，分别为61至309例和26至83例。结论持续增长的需求和全球短缺要求在开始或继续使用免疫球蛋白治疗前仔细考虑适应症。随着全球免疫球蛋白的短缺，仔细考虑和患者选择是重要的。增加免疫球蛋白的使用改善了许多患者的治疗。然而，免疫球蛋白是一种有限的资源，必须谨慎使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Immunology Communications

自引率

0.00%

发文量